Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients

Heitz, 2004, Pancreatic endocrine tumours, 177 Hruban, 2007, Endocrine Neoplasms, 251 Klöppel G, Rindi G, Anlauf M, et al. Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch 2007;451 (Suppl 1). Capelli, 2009, Endocrine neoplasms of the pancreas: pathologic and genetic features, Arch Pathol Lab Med, 133, 350, 10.5858/133.3.350 Hurban, 2007, Endocrine Neoplasms, 259 Oberg, 2005, Endocrine tumours of the pancreas, Best Pract Res Clin Gastroenterol, 19, 753, 10.1016/j.bpg.2005.06.002 Butturini, 2006, Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma, Endocr Relat Cancer, 13, 1213, 10.1677/erc.1.01200 de Herder, 2006, Well-differentiated pancreatic tumor/carcinoma: insulinoma, Neuroendocrinology, 84, 183, 10.1159/000098010 Falconi, 2006, Well-differentiated pancreatic nonfunctioning tumors/carcinoma, Neuroendocrinology, 84, 196, 10.1159/000098012 Jensen, 2006, Gastrinoma (duodenal and pancreatic), Neuroendocrinology, 84, 173, 10.1159/000098009 O'Toole, 2006, Rare functioning pancreatic endocrine tumors, Neuroendocrinology, 84, 189, 10.1159/000098011 Capella, 1995, Revised classification of neuroendocrine tumours of the lung, pancreas and gut, Virchows Arch, 425, 547, 10.1007/BF00199342 Schindl, 2000, Is the new classification of neuroendocrine pancreatic tumors of clinical help?, World J Surg, 24, 1312, 10.1007/s002680010217 Schmitt, 2007, WHO 2004 criteria and CK19 are reliable prognostic markers in pancreatic endocrine tumors, Am J Surg Pathol, 31, 1677, 10.1097/PAS.0b013e31805f675d Rindi, 2006, TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system, Virchows Arch, 449, 395, 10.1007/s00428-006-0250-1 Ekeblad, 2008, Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution, Clin Cancer Res, 14, 7798, 10.1158/1078-0432.CCR-08-0734 Fischer, 2008, Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas, Br J Surg, 95, 627, 10.1002/bjs.6051 La Rosa, 2009, Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors, Hum Pathol, 40, 30, 10.1016/j.humpath.2008.06.005 Pape, 2008, Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors, Cancer, 113, 256, 10.1002/cncr.23549 Harrell, 1996, Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors, Stat Med, 15, 361, 10.1002/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4 Aparicio, 2001, Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours, Eur J Cancer, 37, 1014, 10.1016/S0959-8049(01)00073-9 American Joint Committee on Cancer. Exocrine and endocrine pancreas. In: Edge S, Byrd D, Compton C, et al (eds). AJCC Cancer Staging Manual (ed Seventh). Berlin, Springer, 2010, pp 241–249. Bilimoria, 2007, Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors, J Am Coll Surg, 205, 558, 10.1016/j.jamcollsurg.2007.05.009